U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07743723) titled 'A Study of IOV-5001 in Adults With Advanced Solid Tumors' on July 29.
Brief Summary: A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic Solid Tumors
Unresectable Solid Tumor
Intervention:
BIOLOGICAL: IOV-5001
IOV-5001 will be administered as 2 infusions, which will be a...